Can you please give us some background on your clinical practice and how many patients you manage pain for in a post-operative surgery setting? Are you performing surgeries in the hospital inpatient setting, hospital outpatient, or ambulatory surgical center?

What is your current standard of care for managing pain in these settings?

What were your initial thoughts when Zynrelef was first launched?Did you use Zynrelef in the early launch period?
If so, when it was first approved only with the initial 3 indications, were you hesitant to use it beyond that?

Have you seen an increase in your usage of Zynrelef in the past 4 months since its label extension?

With the label expansion at the end of 2021 to include foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures, does this make you want to try out Zynrelef following additional types of procedures?  Where do you think it may be most useful?

Have you previously used Exparel?  
Is Exparel differentiated at all from older anesthetics like Bupivacaine? 
Given that in the randomized phase 3 clinical trial Zynrelef beat bupivacaine head to head, do you see Zynrelef as a superior pain relief option to Exparel?
If you use Exparel, do you anticipate your usage decreasing in favor of Zynrelef in the near future, and if so, can you comment on what are the factors that drive that (or if not, what reasons you would not switch)

For total knee arthroplasty, do you typically utilize a catheter/pump system in addition to periarticular instillation of meds?  
Are there challenges to this approach?  
Can using Zynrelef in the instillation obviate the need for the pumps?   

Please talk about the use of opioids and whether Zynrelef opioid sparing data was convincing?  Is there a large unmet need for reducing the use of opioids following these surgeries and does that make Zynrelef attractive?

On Zynrelef's 72 hour benefit, is this something that stands out, and does this decrease the need for additional treatments?  What about after the 72 hours?  Is that still meaningful?

In terms of your use of Zynrelef so far, how has access been? Has it gone through P&T committee at your institution?  Going forward has there been any evolution with this over time? 

If you've been using Zynrelef, has it lived up to the expected results as seen in the clinical trials?   Are patients benefitting?  Any patient feedback?

Given the availability of so many options for pain relief with generics, catheter pumps, nerve block, etc. does Zynrelef have an important role in this context?  Do all of these options successfully manage pain or are there limitations and still a strong need for opioids despite these options

Can you comment on the recent approval of Pass Through Status from CMS, and the significance of this as the only local anesthetic to get separate reimbursement outside the surgical bundle for the hospital outpatient setting.  Will this impact your prescribing? Or otherwise how might this impact the field?